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Background: Autism spectrum conditions (ASC) are a group of neurodevelopmental conditions characterized by
difficulties in social interaction and communication alongside repetitive and stereotyped behaviours. ASC are heritable,
and common genetic variants contribute substantial phenotypic variability. More than 600 genes have been implicated
in ASC to date. However, a comprehensive investigation of candidate gene association studies in ASC is lacking.
Methods: In this study, we systematically reviewed the literature for association studies for 552 genes associated with
ASC. We identified 58 common genetic variants in 27 genes that have been investigated in three or more
independent cohorts and conducted a meta-analysis for 55 of these variants. We investigated publication bias and
sensitivity and performed stratified analyses for a subset of these variants.
Results: We identified 15 variants nominally significant for the mean effect size, 8 of which had P values below a
threshold of significance of 0.01. Of these 15 variants, 11 were re-investigated for effect sizes and significance in the
larger Psychiatric Genomics Consortium dataset, and none of them were significant. Effect direction for 8 of the 11
variants were concordant between both the datasets, although the correlation between the effect sizes from the two
datasets was poor and non-significant.
Conclusions: This is the first study to comprehensively examine common variants in candidate genes for ASC through
meta-analysis. While for majority of the variants, the total sample size was above 500 cases and 500 controls, the total
sample size was not large enough to accurately identify common variants that contribute to the aetiology of ASC.
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Autism spectrum conditions (ASC) are a group of neurode-
velopmental conditions characterized by difficulties in so-
cial interaction and communication alongside unusually
repetitive and stereotyped behaviour and unusually narrow
interests [1]. ASC has an estimated heritability of around
50 % [2, 3], and common variants contribute to a significant
proportion of the variability in the condition [3, 4]. ASC is
polygenic and genetic variants, in addition to environmen-
tal, epigenetic and hormonal factors, contribute to ASC risk
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(http://creativecommons.org/publicdomain/zeSequencing and copy number variation analyses have
identified a number of rare, highly penetrant, possibly
causative variants. Strategies to identify common variants
through genome-wide association studies have failed to
produce consistent, replicable results across cohorts [5].
This may be attributed to many factors, including smaller
than required sample size to adequately power these stud-
ies to identify variants with small effects. Over the last
15 years, a large number of studies have investigated com-
mon variants in candidate genes for ASC [6] typically in-
vestigating variants in a small number of genes using a
relatively small sample size. These studies have provided
some evidence of the association of a few genes with ASC,
though they are not rigorous enough to definitively iden-
tify variants and results vary based on ethnicity, sample
size, study methodology and clinical ascertainment [6].le is distributed under the terms of the Creative Commons Attribution 4.0
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summary level data is meta-analysis [7]. Though not
without limitations, meta-analysis provides a fairly ro-
bust statistical framework to systematically analyse ef-
fect sizes [7]. Further, the combined power of a meta-
analysis greatly exceeds the power of the individual
studies in a meta-analysis [7].
In the field of psychiatric genetics, studies have compre-
hensively investigated existing candidate gene studies and
used meta-analysis to investigate genetic associations
[8–10]. In the field of autism genetics, such an overarching
study is lacking and no study, to our knowledge, has pro-
vided a comprehensive overview of ASC genetics. To bridge
this gap, we reviewed the existing literature for 552 genes
implicated in ASC. Using a strict inclusion criteria, we iden-
tified common variants in 27 genes that were investigated in
three or more independent cohorts. We performed meta-
analyses, sensitivity analyses and subgroup analyses for these
common variants and checked for publication bias in a sub-
set of these common variants. This is the first comprehen-
sive study of candidate gene associations in ASC.
Methods
Literature search and inclusion criteria
A preliminary literature search of genes associated
with ASC was performed using SFARI gene (https://
gene.sfari.org/) and HuGE Navigator (http://hugenavi-
gator.net/). Since both of these databases do not com-
pletely document the available literature, we additionally
searched PubMed, Scopus and Google Scholar. The search
terms used were ‘Gene name’ or ‘variant ID’ and ‘Autism’
or ‘Autistic Disorder’ or ‘Asperger Syndrome’.
Studies were included in the meta-analysis if: (1) they
reported effect sizes or statistics to measure effect sizes
and confidence intervals; (2) the studies were either a
case-control association study or a transmission disequi-
librium study of autism; (3) the variants did not deviate
from Hardy-Weinberg Equilibrium (HWE) in the con-
trol group or if the sample size was too small to effect-
ively calculate HWE due to sampling effect. Though we
checked for HWE in family-based studies, this was not a
requirement for including these studies as the study de-
sign overcomes the issue of population stratification; (4)
cases had a diagnosis of an autism spectrum condition
(Autism, PDDNOS, Asperger Syndrome) according to
DSM-IV, DSM-5 or ICD-10 criteria; (5) the global minor
allele frequency (MAF) of the variant investigated was
greater than 0.01; (6) the studies were reported in English
and (7) the common variants were investigated in inde-
pendent cohorts. Authors of the articles were contacted if
sufficient information was absent to use the data for meta-
analysis. In addition to the published studies, we used
unpublished genotype data from two cohorts from our
research group at the Autism Research Centre, Universityof Cambridge. These cohorts are labelled ‘Chakrabarti
[11]’ and ‘Warrier [12]’ in the current study. The char-
acteristics of the two cohorts are described elsewhere
[11, 12]. Details of genotyping and statistical analysis
are provided in Additional file 1. We did not include
data from genome-wide association studies (GWAS)
as there is an overlap between participants in the
candidate gene association studies and the genome-
wide association studies. Since we had access to only
summary data, it was impossible to ascertain the de-
gree of overlap and remove participants accordingly.
Literature search and study inclusion was performed
independently by two researchers (VC and VW) from
March 2014 to September 2014.
Statistical analyses
Meta-analysis was performed only if variants were investi-
gated in three or more independent cohorts. Family-based
association tests (FBATs) studies were not included as ef-
fect sizes are not calculated in FBA. For variants investi-
gated in five or more independent cohorts, we performed a
complete meta-analysis. This included the calculation of ef-
fect size and publication bias, sensitivity analysis and sub-
group analysis. For variants investigated in three to five
independent cohorts, we performed a partial meta-analysis
restricted to the calculation of mean effect size. We did not
perform a meta-analysis for variants investigated in fewer
than three cohorts as there was insufficient power to sig-
nificantly investigate the underlying effect. For variants
with P values <0.05 we calculated fail-safe N.
All analyses were performed using Comprehensive Meta-
Analysis version 2.0 [13]. Meta-analysis was performed
using the inverse-variance weighted method. Heterogeneity
in the reported effects were examined using a fixed and a
random effects model. Heterogeneity was measured using
I2 statistics in conjunction with Q-statistics. A fixed effect
model was applied if the P value for Q-statistics was above
0.05 and I2 was below 60. The random effects model was
used if either the P value was below 0.05 or I2 was above
60, as an I2 above 60 indicates that 60 % of the total ob-
served variation is due to true heterogeneity [7, 10].
Egger’s regression in conjunction with a funnel plot was
used to assess publication bias. Sensitivity analyses were
performed by removing each study from the meta-analysis
and calculating the mean effect size for the remaining
studies. This analysis was used to assess the contribution
of each study to the final weighted effect in the analysis.
Additionally, for the variants with P values <0.05, we com-
puted both classic fail-safe N and Orwin’s fail-safe N to
check the number of studies required to make the P value
non-significant and make the effect size trivial respect-
ively. For Orwin’s fail-safe N, the non-significant odds ra-
tio (OR) was kept at 1.05 or 0.95 depending on the effect
direction. While this is certainly not a trivial effect size, it
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precision given the sample sizes in the meta-analysis. Sub-
group analysis was performed after stratifying based on
ethnicity or study methodology to check if either of these
variables affected the final effect size. We conducted the
subgroup analysis only for variants investigated in five or
more independent cohorts. Meta-analysis was performed
only if there were at least three independent cohorts after
stratification to account for power considerations.
OR and 95 % confidence intervals (CI) were used to
calculate the mean effect size. For transmission disequilib-
rium tests (TDT), odds ratios were calculated according to
methods laid out by Kazeem and Farall [14]. Where pos-
sible, OR and CI were calculated using allele numbers for
case-controls (CC) and transmitted and non-transmitted
numbers for TDT. Where information of OR and CI was
provided for the complement allele of the allele investigated
in the study, the log odds ratio (LOR) and standard error
(SE) were calculated and used in the meta-analysis.
Age was not regarded a confounding variable as ASC
is a neurodevelopmental condition, and genetic varia-
tions are largely invariant across lifespan. However, ASC
has a male-female ratio of 5:1 [5], and sex is a potential
confounding variable as gene expressions can vary based
on sex. However, there was insufficient data to conduct
a stratified analysis based on sex, so this is a limitation
of the current study. Finally, due to the large number of
studies carried out, we adopted a more conservative stat-
istical significance threshold of 0.01. This is similar to
what was used in a similar comprehensive meta-analysis
of obsessive-compulsive disorder [10]. We did not carry
out a Bonferroni correction as the sample for each vari-
ant investigated was very different, and as a result, mul-
tiple tests were not carried out on the same sample.
Analysis of the PGC dataset
While we did not choose to include data from available
GWAS due to potential overlap of participants, we com-
pared the results using the publicly available GWAS data-
set from the Psychiatric Genomics Consortium (PGC). In
the ASC cohort of the PGC dataset, 4788 trio cases and
4788 trio pseudocontrols as well as 161 cases and 526
controls have been genotyped. Details of the cohort, geno-
typing methods and statistical analysis are given elsewhere
[15]. We searched for effect sizes and P values for variants
with P values <0.05 in our meta-analysis. The autism PGC
dataset is the largest available and accessible GWAS
dataset for autism. The sample size of any of the vari-
ants investigated through meta-analysis in the study,
except rs4141463 in MACROD2, is smaller than the
sample size of the PGC autism dataset. Despite this, the
PGC dataset is underpowered to detect variants with
small effects. We were motivated to investigate the top
variants in our study in the PGC dataset to ascertain ifthe candidate variants were at least nominally signifi-
cant (P < 0.05) and if the effect direction was concord-
ant between the two samples.
Results
Literature review
We identified 463 genes that have been tested for genetic
association using HuGE Navigator (as of August 2014).
SFARI Gene reports 616 genes to be associated with autism
(as of August 2014). Only 185 of these genes have been ex-
amined in ASC using genetic association studies. Of these,
we identified 89 genes from the SFARI Gene list that were
not included in the HuGE Navigator list, bringing the total
list of potential genes to 552. We did not identify any add-
itional genes from AutismKB database. Thus, we reviewed
552 genes in total for the meta-analysis.
Scopus, Google Scholar and PubMed were searched for
publications relating to ASC and any of the 552 genes. We
searched for common variations in these genes that have
been investigated for ASC in at least three independent co-
horts. Using the eligibility criteria outlined in the methods
section, we identified 27 genes that could be taken forward
for meta-analysis. In total, there were 58 common variants
across these 27 genes that were investigated in our meta-
analysis. Details of the studies included and excluded for the
27 genes are given in Additional file 1: Tables S1 and S2.
We next searched the literature for existing meta-
analyses for the 58 variants and 27 genes in ASC, identify-
ing existing meta-analyses for OXTR [16], RELN [17],
SLC6A4 [18], HOXA1 [19], HOXB1 [19] andMTHFR [20].
Detailed information of previous meta-analyses is pro-
vided in Additional file 1. As we had additional data and
different inclusion criteria, we performed meta-analyses
for all the variants in these six genes except rs723387731
in HOXB1, STin2 VNTR in SLC6A4 and the GGC repeat
in RELN. These three variants were excluded from the
current meta-analyses as we could not identify additional
data to add to the original meta-analyses. For the sake of
comprehensiveness, we have included the data for these
three variants in our table. Of the remaining 55 variants,
we conducted a complete meta-analysis for 20 variants
and a partial meta-analysis for 35 variants. A flow chart of
the study protocol is given in Fig. 1.
Mean effect sizes
Effect sizes for 15 variants in 12 genes had P values
below 0.05. Nine of these variants had a P value below
0.01. The most significant association was rs167771 in
DRD3 (OR = 1.822, P value = 9.08 × 10−6). Seven other
significant associations with P values <0.01 were in
CNTNAP2 (rs7794745, OR = 0.887, P value = 0.001),
RELN (rs362691, OR = 0.832, P value = 3.93 × 10−5), OXTR
(rs2268491, OR = 1.31, P value = 0.004), SLC25A12
(rs2292813, OR = 1.372, P value = 0.001 and rs2056202,
Fig. 1 Schematic diagram of meta-analysis protocol
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P value = 0.006) and MTHFR (rs1801133, OR = 1.370, P
value = 0.010). As expected for common variants in ASC,
the odds ratios for the alleles tested were small and lay be-
tween 0.781 (0.446–1.368) for MAOA uVNTR and 1.822
(1.398–2.375) for DRD3 rs167771. Details of the variants
analysed, model used and the P values are provided in
Table 1. Forest plots for the nine most significant variants
are in Additional file 1: Figures S1–S8.Subgroup analyses
We performed subgroup analyses, stratifying by ethnicity
and study methodology, for variants originally investi-
gated in five or more independent cohorts. In the strati-
fied analyses, six variants had P values below 0.05. Of
these, the most significant three variants (rs2292813
and rs2056202-SLC25A12, rs362691-RELN) were also
significant in the non-stratified analyses. Stratification
did not increase the significance for these variants. A
variant in EN2 (rs1861973) was significant after stratify-
ing based on both ethnicity (Caucasian only) and study
methodology (TDT). Another variant in EN2 (rs1861972)
was significant after stratifying for study methodology
(TDT). Finally, the STin2 variant in SLC6A4 also exhibited
a significant trend in the Caucasian-only subgroup. This
result indicates that at least for a few variants implicated
in ASC, ethnicity and study methodology can potentially
influence the outcome. Results of the subgroup analyses
are provided in Table 2. Forest plots for the significant
and nominally significant subgroup analyses are provided
in Additional file 1: Figures S9–S15.Publication bias and sensitivity analyses
Publication bias was significant only for one variant,
rs2254298 in OXTR (Egger’s test (two-tailed) P value =
0.03). However, the mean effect size for the variant was
not significant (P value = 0.425). Notably, sensitivity was
significant for some variants. Of the nine variants with P
values below 0.01, we performed sensitivity analyses on
the six variants with data from more than five independ-
ent cohorts (rs7794745, rs362691, rs2292813, rs2056202,
rs1861972, and rs1801133). For rs1801133, most studies
contributed approximately equally, with the exception of
two studies [21, 22]; both of these studies lowered the OR.
A re-analysis of the data after removing either of the two
studies decreased the P value of the OR (original P value
= 0.010, P value after removing Park et al., 2014 [21] =
0.006; P value after removing Schmidt et al., 2011 [22] =
0.003). For rs2056202, the removal of data from one study
[23] increased the P value from P value = 0.002 to P value
= 0.088. Sensitivity was not an issue for the remaining four
variants that were significant. However, of the nominally
significant variants, sensitivity was an issue for rs4446909,
rs736707 and rs1861972. Forest graphs of the sensitivity
analyses for these five variants are provided in Additional
file 1: Figures S16–S20.
Analysis of the PGC dataset
Of the 15 nominally significant variants in the current
meta-analyses, 11 were genotyped in the PGC GWAS
cohort, and none were found to be significant. Effect dir-
ection was concordant for 8 of the 11 variants between
both the datasets. Effect sizes, as expected due to the lar-
ger sample size, were smaller in the PGC dataset for all
the 11 variants, and the odds ratios were closer to 1.
Total sample size was also not a significant predictor of
concordance of effect direction between the two data-
sets. However, inspection of the datasets indicate that
with the exception of rs2056202 in SLC25A12, the other
three variants discordant for effect direction were ana-
lysed in small samples in the meta-analysis (see Table 2).
The lack of significance for 11 of the 15 variants in the
PGC dataset forces us to re-evaluate the significance of
the remaining four variants. For two variants, the classic
fail-safe N is very small (three for rs4446909 in ASMT,
and zero for rs4717806 in STX1A). The latter variant
was analysed using a fixed effect model and becomes
non-significant when analysed using a random effect
model. For the remaining two variants (rs1861972 in EN2
and rs362691 in RELN), the classic fail-safe N is above 10.
The sample sizes, however, are modest. These analyses indi-
cate that the first two variants are likely to be false positives.
With rs1861972, the significance in P value is driven
largely by the TDT-only subset in the original analysis
(P value = 0.013, see Table 2). Both a case-control only
subset and a Caucasian-only subset were not significant
Table 1 Summary of mean effect size analyses
S. No Gene Variants Allele Global MAF Data sets Mean OR
(95% CI)
Z-Value P-Value Model (I2 value) Total
cases
Total
controls
Trios PGC
P-value
Effect direction
(odds ratio)
Classic
fail-safe N
Orwin's fail safe N
(OR = 1.05 or 0.95)
1 DRD3 rs167771 G vs A G=0.4113 3 1.822
(1.398-2.375)
4.44 9.08E-06 Fixed effect (60) 580 754 0 0.6 discordant
(0.980)
7 34
2 RELN rs362691 C vs G C=0.1210 8 0.832
(0.763-0.908)
-4.11 3.93E-05 Fixed effect
(33.2)
765 765 303 NA NA 12 21
3 SLC25A12 rs2292813 C vs T T=0.2085 6 1.372
(1.161-1.621)
3.72 1.97E-04 Fixed effect (0) 465 450 1220 0.78 concordant
(1.014)
5 25
4 CNTNAP2 rs7794745 A vs T A=0.4946 4 0.887
(0.828-0.950)
-3.45 1.00E-03 Fixed effect
(21.2)
322 524 2236 0.18 concordant
(0.9594)
9 6
5 SLC25A12 rs2056202 T vs C T=0.2420 8 1.227
(1.079 -1.396)
3.12 2.00E-03 Fixed effect
(6.5)
756 1211 1220 0.99 discordant
(0.9993)
6 26
6 OXTR rs2268491 T vs C T=0.2137 4 1.31
(1.092 -1.572)
2.91 4.00E-03 Fixed effect (0) 282 440 458 0.54 concordant
(1.026)
3 19
7 EN2 rs1861972 A vs G G=0.242 8 1.125
(1.035-1.224)
2.75 6.00E-03 Fixed effect
(57.6)
669 1704 953 NA NA 16 12
8 MTHFR rs1801133 T vs C A=0.2454 10 1.370
(1.079-1.739)
2.59 1.00E-02 Random effects
(88.2)
2280 7235 0 0.57 concordant
(1.018)
80 40
9 ASMT rs4446909 G vs A A=0.1741 5 1.195
(1.038-1.375)
2.48 1.30E-02 Fixed effect (0) 1066 1074 0 NA NA 3 14
10 MET rs38845 A vs G A=0.3634 3 1.322
(1.013-1.724)
2.41 1.60E-02 Random effects
(66.5)
405 594 419 0.2 concordant
(1.04)
13 15
11 SLC6A4 rs2020936 T vs C G=0.228 4 1.244
(1.036-1.492)
2.35 1.90E-02 Fixed effect
(33.9)
0 0 1068 0.78 concordant
(1.01)
3 14
12 STX1A rs4717806 A vs T A=0.2322 4 0.851
(0.741-0.978)
-2.28 2.30E-02 Fixed effect
(35.3)
653 1007 375 NA NA 0 9
13 RELN rs736707 T vs C G=0.3660 9 1.269
(1.030-1.563)
2.24 2.50E-02 Random effects
(76.5)
975 1695 196 0.31 concordant
(1.035)
126 48
14 PON1 rs662 A vs G T=0.4571 3 0.794
(0.642-0.983)
-2.12 3.40E-02 Fixed effect
(17.5)
334 641 0 0.07 discordant
(1.058)
0 11
15 OXTR rs237887 G vs A G=0.3998 4 1.163
(1.002-1.349)
1.99 4.70E-02 Fixed effect
(0)
282 440 458 0.94 concordant
(1.002)
0 9
16 STX1A rs6951030 G vs T G=0.1771 4 1.383
(0.995-1.922)
1.93 5.40E-02 Random effects
(76.7)
653 1007 375
17 OXTR rs2268493 C vs T C=0.2049 3 0.845
(0.701-1.019)
-1.76 7.80E-02 Fixed effect (54.5) 574 1201 0
18 ASMT rs5989681 G vs C NA 5 1.135
(0.984 - 1.308)
1.74 8.20E-02 Fixed effect (0) 1066 1074 0
19 HOXB1 rs72338773*18 INS vs
nINS
NA 8 1.36
(0.97-
1.33)
NA 1.18E-
01
Fixed Effect
(NA)
362 448
238
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Table 1 Summary of mean effect size analyses (Continued)
20 RELN rs2073559 C vs T C=0.4746 3 0.955
(0.900-1.014)
-1.5 1.35E-01 Fixed effect (64.5) 437 493 473
21 RELN GGC
repeat*16
NA NA 7 1.11
(0.80–1.54)
NA 1.53E-01 Fixed effect (0) 878 1170 167
22 GLO1 rs2736654 A vs C G=0.2873 4 1.307
(0.882 - 1.936)
1.34 1.82E-01 Random effects
(68.7)
857 680 0
23 PON1 rs854560 A vs T T=0.1827 3 1.140
(0.931 - 1.395)
1.27 2.05E-01 Fixed effect (0) 334 641 0
24 TPH2 rs11179000 T vs A T=0.3988 3 1.130
(0.934-1.366)
1.26 2.08E-01 Fixed effect (0) 224 260 352
25 MET rs1858830 G vs C G=0.4575 8 0.905
(0.773-1.061)
-1.23 2.19E-01 Random effect
(67.5)
1975 1589 798
26 OXTR rs2268490 T vs C T=0.2584 5 1.135
(0.920-1.400)
1.18 2.38E-01 Fixed effect (0) 292 761 458
27 OXTR rs2301261 A vs G T=0.1248 4 1.127
(0.889-1.430)
0.99 3.22E-01 Fixed effect (39.1) 650 1300 0
28 HOXA1 rs10951154 G vs A C=0.2192 13 0.925
(0.791-1.081)
-0.98 3.28E-01 Fixed effect (35.7) 705 998 425
29 BDNF rs6265 G vs A T=0.2013 3 0.919
(0.763-1.107)
-0.89 3.72E-01 Fixed effect (0) 303 469 140
30 HTR2A rs6311 A vs G T=0.4435 6 0.871
(0.643-1.181)
-0.89 3.74E-01 Random effects
(74.8)
179 313 396
31 ITGB3 rs5918 C vs T C=0.0889 3 0.866
(0.630-1.191)
-0.88 3.77E-01 Fixed effect (37.1) 139 165 363
32 MAOA uVNTR short vs
long
NA 3 0.781
(0.446 - 1.368)
-0.86 3.87E-01 Random effects
(72)
436 469 0
33 MACROD2 rs4141463 T vs C C=0.3818 7 0.913
(0.734-1.135)
-0.82 4.11E-01 Random effects
(87.1)
1170 35307 1158
34 OXTR rs2254298 A vs G A=0.2071 5 0.813
(0.489-1.352)
-0.8 4.25E-01 Random effects
(82.5)
650 1306 57
35 ASMT rs6644635 C vs T NA 4 1.056
(0.906 -1.230)
0.69 4.88E-01 Fixed effect (29.3) 788 819 0
36 SLC6A4 rs2020942 A vs G T=0.2550 3 1.062
(0.881-1.281)
0.63 5.28E-01 Fixed effect (0) 0 0 678
37 OMG rs11080149 A vs G T=0.0409 4 0.847
(0.477 - 1.506)
-0.56 5.72E-01 Random effects
(43.8)
65 131 431
38 ADA rs7359837 G vs A A=0.0282 3 1.375
(0.401 - 4.717)
0.51 6.13E-01 Random effects
(89.1)
334 445 0
39 OXTR rs237894 G vs C C=0.1615 5 0.961
(0.818-1.129)
-0.48 6.26E-01 Fixed effect (4) 292 761 458
40 OXTR rs53576 A vs G A=0.3894 5 0.966
(0.839-1.113)
-0.48 6.31E-01 Fixed effect (44.9) 650 1300 57
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Table 1 Summary of mean effect size analyses (Continued)
41 OXTR rs2268494 A vs T A=0.0683 4 1.076
(0.760 -1.510)
0.42 6.73E-01 Fixed effect (0) 76 99 458
42 SLC6A4 STin2
VNTR*17
12 vs 9/
10
NA 8 1.129
(0.819–1.558)
NA 6.73E-01 Random effects
(68.7)
0 0 814
43 NF1 GxAlu 9 vs
non-9
NA 4 1.131
(0.633 - 2.022)
0.42 6.77E-01 Random effects
(85.7)
262 312 0
44 GRIK2 rs2227281 T vs C T=0.2738 4 0.929
(0.603-1.432)
-0.34 7.32E-01 Random effects
(77.3)
0 0 508
45 OXTR rs2268495 A vs G A=0.2406 4 1.059
(0.763 - 1.468)
0.34 7.33E-01 Fixed effect (60.4) 282 446 458
46 SHANK3 rs9616915 C vs T C=0.3433 3 0.974
(0.834 - 1.138)
-0.33 7.44E-01 Fixed effect (60.1) 340 863 308
47 HTR2A rs6314 T vs G A=0.0747 4 0.949
(0.691-1.304)
-0.32 7.47E-01 Fixed effect (18.3) 103 214 370
48 CNTNAP2 rs2710102 T vs C A=0.4113 3 0.989
(0.924-1.059)
-0.31 7.60E-01 Fixed effect (17.3) 322 524 2051
49 OXTR rs237885 G vs T G=0.4884 6 0.981
(0.868 - 1.109)
-0.3 7.62E-01 Fixed effect (0) 574 1201 458
50 COMT rs4680 Met vs
Val (A
vs G)
A=0.3692 5 0.982
(0.851-1.134)
-0.24 8.08E-01 Fixed effect (49) 814 741 35
51 MTHFR rs1801131 C vs A G=0.2494 6 0.979
(0.824-1.164)
-0.24 8.11E-01 Random effects
(56.3)
1854 6819 0
52 OXTR rs1042778 G vs A T=0.4109 4 1.02
(0.849-1.225)
0.21 8.33E-01 Fixed effect (0) 282 440 458
53 GRIK2 rs2227283 A vs G A=0.3275 4 0.967
(0.686-1.363)
-0.19 8.51E-01 Random effects
(65.65)
0 0 508
54 EN2 rs3735653 T vs C T=0.4097 4 1.007
(0.870-1.165)
0.09 9.28E-01 Fixed effect (0) 174 349 499
55 NF1 GxAlu 8 vs
non-8
NA 4 0.982
(0.602 - 1.601)
-0.07 9.41E-01 Random effects
(79.2)
262 312 0
56 SLC6A4 5-HTTLPR short vs
long
NA 17 0.994
(0.847-1.167)
-0.07 9.42E-01 Random effects
(63.8)
0 0 2039
57 HTR2A rs6313 T vs C A=0.4413 3 1.007
(0.812-1.249)
0.07 9.47E-01 Fixed effect (0) 0 0 303
58 EN2 rs1861973 T vs C T=0.2410 6 1.004
(0.775-1.300)
0.03 9.77E-01 Random effects
(80.8)
669 1704 681
Rows highlighted in bold show variants with P values below 0.01
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Table 2 Summary of subgroup analyses
S.No Gene Variant Allele Data sets Subgroup Mean OR (95% CI) Z-Value P-Value Model
1 ASMT rs4446909 G vs A 3 Caucasian 1.135 (0.886 - 1.454) 1 3.16E-01 Fixed
2 ASMT rs5989681 G vs C 3 Caucasian 1.065 (0.841 - 1.349) 0.52 6.03E-01 Fixed
3 COMT rs4680 A vs G 4 TDT 0.973 (0.840 - 1.128) −0.36 7.17E-01 Fixed
4 EN2 rs1861973 T vs C 4 TDT 0.86 (0.791 - 0.954) −2.94 3.00E-03 Fixed
5 EN2 rs1861973 T vs C 3 Caucasian 0.880 (0.801 - 0.969) −2.26 9.00E-03 Fixed
6 EN2 rs1861972 A vs G 4 Case–control 1.186 (0.876 - 1.605) 1.11 2.69E-01 Random
7 EN2 rs1861972 A vs G 4 TDT 1.126 ( 1.025 - 1.238) 2.47 1.30E-02 Fixed
8 EN2 rs1861972 A vs G 4 Caucasian 1.118 (0.807 - 1.549) 1.32 1.86E-01 Fixed
9 HOXA1 rs10951154 A vs G 6 Case–control 0.876 (0.675 - 1.137) −0.99 3.21E-01 Random
10 HOXA1 rs10951154 A vs G 6 Caucasian 0.887 (0.661 - 1.190) −0.8 4.23E-01 Random
11 HOXA1 rs10951154 A vs G 7 TDT 0.963 (0.784 - 1.159) −0.48 6.32E-01 Random
12 HTR2A rs6311 A vs G 4 TDT 0.893 (0.602 - 1.325) −0.56 5.73E-01 Random
13 HTR2A rs6311 A vs G 3 Caucasian 0.929 (0.542 - 1.594) −0.27 7.90E-01 Random
14 MACROD2 rs4141463 T vs C 5 Case–control 1.033 (0.944 - 1.131) 0.71 4.78E-01 Random
15 MET rs1858830 G vs C 7 Case–control 0.889 (0.749 - 1.056) −1.34 1.80E-01 Random
16 MET rs1858830 G vs C 3 Italian 0.924 (0.592 - 1.444) −0.35 7.29E-01 Random
17 MTHFR rs1801133 T vs C 4 Caucasian 1.398 (1.249 - 1.565) 5.82 6.60E-02 Random
18 MTHFR rs1801131 C vs A 3 Caucasian 0.904 (0.782 - 1.044) −1.37 1.71E-01 Fixed
19 OXTR rs237885 G vs T 3 Case–control 0.950 (0.817 – 1.106) −0.65 5.11E-01 Fixed
20 OXTR rs2268490 T vs C 3 TDT 1.281 (0.953 - 1.721) 1.64 1.01E-01 Fixed
21 OXTR rs2254298 A vs G 4 Caucasian 0.664 (0.357 - 1.235) −1.29 1.96E-01 Fixed
22 OXTR rs2268490 T vs C 4 Caucasian 1.114 (0.882 - 1.409) 0.91 3.66E-01 Fixed
23 OXTR rs237885 G vs T 4 Caucasian 1.039 (0.885 - 1.220) 0.47 6.40E-01 Fixed
24 OXTR rs237885 G vs T 3 TDT 1.043 (0.846 - 1.285) 0.39 6.96E-01 Fixed
25 OXTR rs2254298 A vs G 4 Case–control 1.034 (0.693 - 1.542) 0.16 8.69E-01 Fixed
26 RELN rs362691 C vs G 6 Case–control 0.857 (0.783 - 0.939) −3.32 1.00E-03 Fixed
27 RELN rs736707 T vs C 8 Case–control 1.187 (0.953 - 1.479) 1.53 1.27E-01 Random
28 RELN rs736707 T vs C 3 Caucasian 1.307 (0.843 - 2.025) 1.2 2.32E-01 Random
29 SLC25A12 rs2292813 C vs T 4 TDT 1.419 (1.158- 1.740) 3.52 7.33E-04 Fixed
30 SLC25A12 rs2056202 T vs C 5 TDT 1.275 (1.097 - 1.482) 3.17 2.00E-03 Fixed
31 SLC25A12 rs2056202 T vs C 3 Case–control 1.105 (0.862 - 1.416) 0.79 4.31E-01 Fixed
32 SLC25A12 rs2056202 T vs C 4 Caucasian 1.087 (0.873 - 1.355) 0.75 4.55E-01 Fixed
33 SLC6A4 5-HTTLPR short vs long 5 Caucasian 0.960 (0.650 - 1.418) −0.2 8.38E-01 Fixed
34 SLC6A4 STin2 VNTR 12 vs 9/10 4 Caucasian 1.492 (1.068 - 2.083) 2.34 1.90E-02 Fixed
Rows highlighted in bold show variants with P values below 0.05
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(r2 = 1), and the two variants are separated by 152 base
pairs. In this study, we used the random effects model to
meta-analyse rs1861973 and it was not significant. Stratify-
ing by both study methodology and ethnicity reduced the
heterogeneity considerably, allowing us to use a fixed effect
model. For rs1861973, both a Caucasian-only and a TDT-
only subset were significant (see Table 2) but this variant
was not significant in the larger Caucasian-only PGCcohort. Additional research in a larger, well-powered sam-
ple is required to confirm the significance of the two
variants.
Discussion
This is the first study to comprehensively investigate can-
didate gene association studies of common variants in
ASC. Using two databases, we identified 552 genes that
are reported to be implicated in ASC through genetic
Warrier et al. Molecular Autism  (2015) 6:49 Page 9 of 11association studies. We scanned the literature for these
552 genes and, using a strict inclusion criteria, we identi-
fied 27 genes that had sufficient data to perform a meta-
analysis. Eight variants across seven genes were significant
for combined effect sizes with P values below 0.01. Data
for 11 variants was present in the PGC GWAS dataset.
None of the 11 variants were significant in the PGC data-
set though the majority of the variants were concordant
for effect direction in both the datasets.
Effect sizes for most common variants are modest for
ASC, and these results are consistent with this observa-
tion. However, there was no clear correlation between
effect sizes in our dataset and the PGC dataset. Effect
sizes were smaller in the PGC dataset. While most of
the effects lay between 0.8 and 1.2, which is expected
from GWAS data, for some variants, the effect was lar-
ger. Our most significant variant (rs167771) had data
only from three studies and had a relatively high OR of
1.82 to 1.40–2.38. The small sample size for this variant
inflated the OR making it significant. The effect direc-
tion was discordant for the variant in the PGC dataset,
and it was not significant in this dataset.
While the sample sizes for most variants were com-
petitive for candidate gene association studies (above
500 total cases and 500 total controls), these are not
sufficient to accurately calculate effect sizes. Addition-
ally, the different study methodologies and ethnicities
contributed to heterogeneity in the sample which poten-
tially confounded the analyses. It is clear from this study
that significant heterogeneity exists for a large fraction
of the variants tested. In fact, heterogeneity is signifi-
cantly and positively correlated with the number of inde-
pendent datasets included per variant in the analyses,
indicating that the current study may not have uncov-
ered all the heterogeneity. We were able to remove some
of the heterogeneity after stratifying for ethnicity and
study methodology, but heterogeneity influenced the
results for some for the variants even after this. This in-
dicates that other additional factors contribute to vari-
ance in the effect. One potential source of heterogeneity
is finer population stratification. Fine-scale population
stratification cannot be addressed in candidate gene asso-
ciation studies as these test only a few variants. Further,
HWE which is used to check for population admixture
among other issues is performed individually for each
variant in these studies thereby failing to utilize multi-
marker information to correct for population stratifica-
tion. We were unable to stratify based on sex or clinical
ascertainment two factors known to contribute to hetero-
geneity in ASC. It is unclear how clinical heterogeneity
maps onto genetic heterogeneity in ASC. Existing genetic
studies that stratify based on IQ or other clinical
phenotype and subphenotypes have had limited success
[24, 25]. The inability to completely identify sources ofheterogeneity forced us to choose between two models
(fixed effect vs. random effects), when most variants are
likely to have varying levels of heterogeneity. This is a
significant concern for meta-analyses using candidate gene
association studies. Even if sample sizes reach competitive
levels, there are no techniques currently available that can
accurately account for potential confounders such as
ethnicity and study methodology. Both these issues can be
satisfactorily addressed in GWAS.
Another cause for concern is the small number of
genes with enough data to meta-analyse. Of 552 genes,
we had data for only 27 of these, less than 5 %. None of
the 27 genes analysed were ASC risk genes as predicted
by DAWN [26]. Further, with the exception of RELN
[27] and SHANK3 [28], none of these genes have suffi-
cient evidence to categorize them as risk genes using se-
quencing or copy number variation studies [27–31]. A
few genes in the list of 552 genes but absent from the
final list of 27 genes are predicted to be ASC risk genes.
This includes GABRB3, GRIN2B and SCN2A. However,
there was not enough evidence to evaluate the role of
common variants in ASC for these genes through the
current meta-analysis.
The majority of the studies analysed were of Caucasian
ethnicity. We were able to stratify for a Caucasian ethni-
city for some of the variants, but were not able to stratify
for other ethnicities due to power considerations. It is
also noteworthy that the PGC autism dataset used a
Caucasian sample for analyses, and to our knowledge,
there is no well-powered GWAS that investigates the
role of common variants in autism in other ethnicities.
Since the minor allele frequencies of the alleles
tested and the variants tagged by these allele can
vary depending on ethnicity, this makes it difficult to
compare the results of the non-stratified meta-analyses
with the PGC autism dataset. Replicating the top variants
in well-powered samples from different ethnicities will
help understand the ethnicity-specific risk for each
variant.
The candidate gene association studies typically have
small samples, which overestimate effect sizes. The lack
of replication do not indicate that these loci do not con-
tribute to the aetiology of ASC, but, rather, that there is
insufficient evidence to implicate it in ASC. ASC is highly
polygenic, and more than 49 % of its heritability can be
attributed to common variants [3]. As effect size for each
individual common variant are likely to be very modest and
not likely to exceed an OR of 1.3, this indicates that there
are several common variants that contribute to the condi-
tion. Disentangling this would require very large sample
sizes, much larger than those in the current PGC autism
GWAS. It is evident, from the current study, that candidate
gene association studies in ASC have been underpowered
to reliably detect causative variants with precision.
Warrier et al. Molecular Autism  (2015) 6:49 Page 10 of 11Conclusions
While recent studies [2, 3] have identified that common
variants, en masse, contribute to a significant fraction of
ASC, there have not been any sufficiently powered stud-
ies to date to identify important common variants. We
attempted to address this issue using a meta-analysis of
candidate gene association studies. Though this is the
first comprehensive study of candidate gene association
studies in ASC, it failed to identify causative vari-
ants—11 of 15 variants with P values <0.05 were not sig-
nificant in a larger sample from the PGC. Data was
unavailable for the remaining five variants in the PGC
dataset. We discuss the potential issues with such an ap-
proach and underline the need for much larger sample
sizes to accurately identify common variants that con-
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